| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFB1 |
| Uniprot No | P60022 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-68aa |
| 氨基酸序列 | GNFLTGLGHR SDHYNCVSSG GQCLYSACPI FTKIQGTCYR GKAKCCK |
| 预测分子量 | 5.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFB1重组蛋白的3篇参考文献及摘要概括：
1. **文献名称**: *"Recombinant human beta-defensin 1 regulates inflammatory responses in human keratinocytes"*
**作者**: Chen X. et al.
**摘要**: 该研究利用重组人DEFB1蛋白处理人角质形成细胞，发现其可通过调控TLR/NF-κB信号通路抑制炎症因子(如IL-6和TNF-α)的表达，提示DEFB1在皮肤免疫调节中的潜在作用。
2. **文献名称**: *"Expression and purification of human beta-defensin 1 in Escherichia coli for antimicrobial studies"*
**作者**: Li Y. et al.
**摘要**: 作者报道了一种在大肠杆菌中高效表达重组DEFB1的优化方法，通过亲和层析纯化后，验证了其对革兰氏阴性菌(如大肠杆菌)的抗菌活性，为后续抗菌药物开发提供基础。
3. **文献名称**: *"Structural and functional characterization of recombinant human beta-defensin 1 as a potential therapeutic agent"*
**作者**: Zhang R. et al.
**摘要**: 该研究通过圆二色谱和核磁共振解析了重组DEFB1的二级结构，并证实其通过破坏病原体细胞膜发挥抗菌功能，同时在小鼠模型中显示出低细胞毒性和抗感染疗效。
---
**备注**：上述文献为示例性内容，实际文献需通过PubMed或Web of Science检索。部分研究可能需关注重组蛋白表达系统(如原核/真核)、功能验证(抗菌/免疫调节)或疾病模型应用。
DEFB1 (Defensin Beta 1), also known as human beta-defensin 1 (hBD-1), is a small cationic antimicrobial peptide belonging to the defensin family, a critical component of the innate immune system. It is constitutively expressed in epithelial tissues, particularly in the respiratory, urinary, and gastrointestinal tracts, as well as the skin, where it serves as a first-line defense against microbial pathogens. Structurally, DEFB1 contains six conserved cysteine residues forming three intramolecular disulfide bonds, contributing to its stability and antimicrobial activity.
As a multifunctional peptide, DEFB1 exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses by disrupting microbial membranes via electrostatic interactions. Beyond direct pathogen neutralization, it acts as a chemoattractant for immune cells (e.g., dendritic cells and T-cells) and modulates inflammatory responses, bridging innate and adaptive immunity. Its expression can be regulated by microbial exposure, cytokines, and cellular stress, though it is less inducible compared to other beta-defensins like hBD-2 or hBD-3.
Recombinant DEFB1 protein, produced through genetic engineering in systems like *E. coli* or yeast, retains these bioactive properties and is widely used in research to study host-pathogen interactions, mucosal immunity, and therapeutic potential. Applications include exploring its role in chronic inflammatory diseases, infections, and cancer immunotherapy. Challenges in clinical translation involve optimizing its stability *in vivo* and addressing potential cytotoxicity at high concentrations. Current studies also investigate DEFB1 polymorphisms linked to disease susceptibility, emphasizing its dual role as a therapeutic agent and biomarker in personalized medicine.
×
